科研动态PubMed 摘要

多发性硬化患者的血液胶质纤维酸性蛋白:一项系统综述与荟萃分析。

PubMed 学科轮询 · 2026-09-19

完整摘要 · 中文译文

背景:新出现的证据表明,胶质纤维酸性蛋白(GFAP)可能有助于追踪多发性硬化(MS)的疾病活动性和进展,特别是在区分复发型和进展型方面。本研究旨在系统评估MS患者与健康对照者以及不同MS亚型之间的血液GFAP水平。 方法:我们系统检索了PubMed和Web of Science截至2025年2月20日的文献,纳入报告MS患者和对照者血液GFAP水平的研究。使用诊断准确性研究质量评价(QUADAS)工具评估偏倚风险。效应量采用Hedges' g计算。当异质性显著(I² > 50%)时采用随机效应模型,否则采用固定效应模型。异质性采用I²统计量评估,发表偏倚通过漏斗图及Egger's和Begg's检验评估。 结果:从581条记录中,纳入20项研究,共2,808名参与者。MS患者的血液GFAP水平显著高于对照者(SMD = 0.94;95% CI [0.62, 1.25];I² = 92.15%;p < 0.001)。我们还发现所有主要MS亚型的GFAP水平均升高:复发缓解型MS(RRMS)(SMD = 0.76;95% CI [0.36, 1.16];I² = 91.12%;p < 0.001)、SPMS(SMD = 0.76;95% CI [0.53, 0.98];I² = 0.00%;p < 0.001)、PPMS(SMD = 1.55;95% CI [0.11, 2.29];I² = 96.57%;p = 0.03)以及合并PMS(SMD = 1.12;95% CI [0.49, 1.75];I² = 94.41%;p < 0.001)均较对照者升高。此外,PMS患者的GFAP水平显著高于R RMS(标准化均数差(SMD)= 0.64;95%置信区间(CI)[0.34, 0.94];I² = 78.19%;p < 0.001)。 结论:我们的研究结果提示,血液胶质纤维酸性蛋白(GFAP)可能作为多发性硬化(MS)疾病进展和亚型监测的支持性生物标志物。鉴于其非特异性及个体间变异性,其最大的临床潜力可能在于纵向评估而非单时间点诊断。仍需进一步研究以验证其与现有工具联合用于追踪疾病活动度和治疗结局的价值。

完整摘要 · 英文原文

BACKGROUND: Emerging evidence suggests that Glial fibrillary acidic protein (GFAP) may help track disease activity and progression in multiple sclerosis (MS), particularly in distinguishing between relapsing and progressive forms. This study aims to systematically assess blood GFAP levels in MS patients compared to healthy controls and across different MS subtypes. METHODS: We systematically searched PubMed and Web of Science up to February 20, 2025, for studies reporting blood GFAP levels in patients with MS and controls. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Effect sizes were calculated using Hedges' g. A random effects model was applied when heterogeneity was significant (I² > 50%), and a fixed effects model otherwise. Heterogeneity was assessed using the I² statistic, and publication bias was evaluated through funnel plots and Egger's and Begg's tests. RESULTS: From 581 records, 20 studies with a total of 2,808 participants were included. Blood GFAP levels were significantly higher in MS patients compared to controls (SMD = 0.94; 95% CI [0.62, 1.25]; I² = 92.15%; p < 0.001). We also found elevated GFAP levels in all major MS subtypes: relapsing-remitting MS (RRMS) (SMD = 0.76; 95% CI [0.36, 1.16]; I² = 91.12%; p < 0.001), SPMS (SMD = 0.76; 95% CI [0.53, 0.98]; I² = 0.00%; p < 0.001), PPMS (SMD = 1.55; 95% CI [0.11, 2.29]; I² = 96.57%; p = 0.03), and combined PMS (SMD = 1.12; 95% CI [0.49, 1.75]; I² = 94.41%; p < 0.001) compared to controls. Additionally, GFAP levels were significantly higher in PMS than in RRMS (SMD = 0.64; 95% CI [0.34, 0.94]; I² = 78.19%; p < 0.001). CONCLUSIONS: Our findings suggest that blood GFAP may serve as a supportive biomarker for disease progression and subtype monitoring in MS. Given its non-specific nature and interindividual variability, its greatest clinical potential may lie in longitudinal assessment rather than single-time-point diagnostics. Further studies are needed to validate its use alongside established tools for tracking disease activity and therapeutic outcomes.

English
Blood glial fibrillary acidic protein in patients with multiple sclerosis: a systematic review and meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界